'Halftime Report' Final Trades: CVS, Moderna And More

On CNBC's "Halftime Report," the investment committee gave their final trades.

Sand Hill Global Advisors' Brenda Vingiello says she likes CVS Health Corporation CVS and notes the company will be participating in the overall rollout of the COVID-19 vaccine once it's approved, which will benefit the company.

Short Hills Capital Managing Partners' Steve Weiss says he likes Moderna, Inc. MRNA and believes the stock could hit the $200 level once the company's vaccine receives emergency use authorization.

Virtus Investment Partners' Joe Terranova says he likes Teradyne, Inc. TER.

Requisite Capital's Bryn Talkington says she likes ARK Innovation ETF ARKK and believes this is a great long-term investment.